Global Respiratory Partnering Deal trends, players and financials Current Partnering Reports

Global Respiratory Partnering Deal trends, players and financials Current Partnering Reports

It has not been prepared in accordance with legal requirements designed to promote the independence of investment research and it is not subject to any prohibition on dealing ahead of the dissemination of investment research. TDRL does not hold any positions in any of the companies mentioned in the report, although directors, employees or consultants of TDRL may hold positions in the companies mentioned. Once fibrosis is established, control of inflammation with even biologics is not sufficient to halt fibrosis progression as matrix stiffness can drive fibrosis independently of intestinal inflammatory activity. Hence anti-inflammatory treatment is best suited for early-stage disease, as fibrosis might become self-perpetuating once ECM activity has become established.

  • Redx Pharma specialises in the discovery and early clinical development of small molecule therapeutics, with an emphasis on oncology and fibrotic disease.
  • Management has also disclosed that it has a research-stage DDR (discoidin domain receptor) inhibitor programme, with lead optimisation the next expected milestone.
  • Tissue responses to injury involve coordinated activities of multiple cell types that, when appropriate in duration and magnitude, restore normal tissue structure and function.
  • These are initially being explored in models of fibrotic disease and offer the potential of disease modifying activities.

Redx’s strategic partnership with Caris Life Sciences should help accelerate US recruitment of MSS mCRC patients into the PORCUPINE trial. Caris’s molecular profiling and screening capabilities enable the identification of eligible patients more quickly, that can then be trial matched with its own network of US trial sites.

Four other Porcupine inhibitors in the clinic

This document does not constitute, nor form part of, and should not be construed as, any offer for sale or purchase of (or solicitation of, or invitation to make any offer to buy or sell) any Securities (which may rise and fall in value). Nor shall it, or any part of it, form the basis of, or be relied on in connection with, any contract or commitment whatsoever. The information that we provide is not intended to be, and should not in any manner whatsoever be, construed as personalised advice. Self-certification by investors can be completed free of charge at TDRL, its affiliates, officers, directors and employees, and ED will not be liable for any loss or damage arising from any use of this document, to the maximum extent that the law permits. Looking at related corporate activity, Loxo Oncology was acquired in 2019 by Eli Lilly for $8bn (Loxo had acquired Redx’s RXC005, BTK inhibitor, for $40m in 2017) and Sanofi acquired Kadmon, for the ROCK2 inhibitor Rezurock (belumosudil), for $1.9bn in 2021.

RXC004: in Phase II proof-of-concept trials

This became LOXO-305 (now pirtobrutinib) and, interestingly, when Eli Lilly acquired Loxo in 2019 for $8bn, LOXO-305 was cited as one of the key desired programmes. Pirtobrutinib is currently in multiple Phase III trials for various haematological cancers. A rolling NDA submission with the FDA seeking accelerated approval in the lead indication, mantle cell lymphoma, is underway; an approval decision is expected early 2023. The current pipeline has a clear focus on highly selective small molecules for the treatment of genetically defined tumours and poorly treated fibrotic diseases. The pipeline is sourced from the in-house discovery platform which aims to create both first-in-class molecules that address novel and biologically relevant targets and best-in-class drugs that are directed at already proven and characterised targets.

Porcupine (Porcn) is a membrane-bound enzyme (MBOAT) that enables a key step required for the secretion, transportation, and activity of Wnt ligands. The Wnt (Wingless type) signalling pathways are increasingly recognised as an attractive, albeit challenging, drug target. Gradients of diverse Wnt proteins regulate fundamental processes such as cell development, renewal, and differentiation, hence their important roles in oncology and fibrosis indications. Redx Pharma has a proven discovery platform, underpinned by the strength of its medicinal chemistry expertise.

Deja una respuesta

Tu dirección de correo electrónico no será publicada. Los campos obligatorios están marcados con *